Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis

Am J Respir Crit Care Med. 2023 Apr 1;207(7):816-818. doi: 10.1164/rccm.202212-2262ED.

Authors

Gustavo E Velásquez^{1

2}, Payam Nahid^{1

3}

Affiliations

¹ UCSF Center for Tuberculosis.
² Division of HIV, Infectious Diseases, and Global Medicine University of California San Francisco San Francisco, California.
³ Division of Pulmonary and Critical Care Medicine University of California San Francisco San Francisco, California.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Antitubercular Agents / therapeutic use
Humans
Nitroimidazoles*
Rifamycins*
Tuberculosis* / drug therapy

Substances

pretomanid
Antitubercular Agents
Nitroimidazoles
Rifamycins

Grants and funding